INS and type 1 diabetes mellitus: With the aim to target non‐beta cell–specific inflammatory component, some randomized controlled trials targeting innate immune mediators [such as interleukin (IL)‐6R, tumor necrosis factor alpha [TNFα], and IL‐1] were developed to preserve insulin secretion in stage 3 type 1 diabetes (11–15).